Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03900910

Gastric Cancer Prevention for Indigenous Peoples

The incidence of gastric cancer in local indigenous peoples is higher than the non-Indigenous counterpart in Taiwan. How to design an effective prevention strategy for gastric cancer is of importance. The present study aimed to identify the causes that may account for the health inequalities, allowing generation of a plan of action on the whole population scale.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Gastric Cancer Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases Stomach Neoplasms

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Taiwan University Hospital

Taipei, Taiwan, 10002

Location status: Recruiting

Location contact

Yi-Chia Lee, MD, PhD

CONTACT

[email protected]

886-2-23123456 ext. 63351

About this study

Owing to the continuing gap in cancer burden between Indigenous and non-Indigenous peoples, reducing health disparities has drawn worldwide attention. Evidence indicates that the gastric cancer incidence and mortality rates in Indigenous peoples are much higher than those of non-Indigenous counterparts living in the same areas. Exposure to more risk factors from social habits, lifestyle, and Helicobacter pylori infection has been considered the cause. However, even though gastric cancer has been repeatedly shown to be preventable by eliminating risk factors, eradication policies are rarely designed for Indigenous peoples. Possible obstacles may include the lack of Indigenous health statistics, inadequate access to care, difficulty in modifying social habits and lifestyles, and the presence of environmental and cultural barriers. Developing and implementing a preventive strategy following the evidence-based principle remains a challenge.

In Taiwan, the number of Indigenous peoples has grown; however, their life expectancy remains substantially lower than that of the non-Indigenous population. Cancer is the most prevalent cause of death for Indigenous peoples and a disproportionate prevalence of certain kinds of cancer is noted for Indigenous peoples. These observations provide an opportunity to establish a plan of action, in which a specific intervention is developed to decrease the threat from each specific cancer so that the overall disparate burden can be reduced in a stepwise manner.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 20-60 years
  • Mentally competent to be able to understand the consent form
  • Able to communicate with study staff for individuals

Exclusion criteria

  • Pregnancy
  • Individuals with major comorbid diseases

Treatment and study plan

Gastric cancer prevention

Other

Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.

Execution of the program

Other

Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .

Primary outcomes

  1. Gastric cancer incidence

    Time frame: After at least 5 years, the gastric cancer incidence per 100,000 person-years is calculated by the person-years of follow-up.

    To assess the effect of H. pylori eradication for gastric cancer prevention

  2. Helicobacter eradication rate

    Time frame: At least 5 years

    To assess the eradication rate of anti-H. pylori treatment.

  3. The participation rate

    Time frame: Screening program quality indicator

    The number of participants divided by the number of invitees

  4. The positivity rate

    Time frame: Screening program quality indicator

    The number of positive test results divided by the number of participants

  5. The referral-to-treatment rate

    Time frame: Screening program quality indicator

    The number of individuals who received anti-H pylori treatment divided by the number of positive test results

  6. The reinfection rate

    Time frame: Screening program quality indicator

    The number of positive test results divided by the person-years of follow-up

Study contacts

Contact information is provided by the study sponsor or research team.

Yi-Chia Lee, MD, PhD

CONTACT

[email protected]

886-2-23123456 ext. 63351

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Collaborators

  • Ministry of Health and Welfare, Taiwan

Registry information

Official study title

A Gastric Cancer Prevention Program for Aboriginal People Living in the Remote Areas

Important dates

Study start
2018
Primary completion
2030
Study completion
2030
First posted
Apr 3, 2019
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.